UniQure shares were halted at $14.09 in premarket trading after the company reported positive topline results for Phase I/II study of AMT-130 for the treatment of Huntington's disease.

UniQure shares tripled, to $41.27, in early Wednesday trading after the company said it had positive topline results for a Phase I/II study of AMT-130 for the treatment of Huntington's disease, and ...

The Wenatchee School District is preparing to ask voters to approve a $294 million bond next year, saying aging ...

Sex differences significantly influence Huntington’s disease outcomes, with women showing slower brain atrophy but greater ...

After 36 months, patients treated with high dose AMT-130 saw a 75% slowing of disease progression vs the external control.

AMT-130 has been granted Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...

Shares of Uniqure NV (NASDAQ:QURE) were trading at $43.52, up $29.86, or 218%, after the Amsterdam-based firm disclosed positive top-line data from the pivotal phase I/II study of AMT-130 for the ...

About Kaia Health Kaia Health is a global leader in digital therapeutics, providing evidence-based programs for chronic disease management. Its clinically validated Kaia Breathe solution brings ...

The single-dose gene therapy has been shown to dramatically slow the relentless, destructive advance of Huntington’s disease.

Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximaland Submaximal Exercise Capacity and Recovery Compared to ...